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1. Introduction  
It is well established that many antidepressant compounds with proven clinical efficacy act 
on the serotonergic and noradrenergic pathways. The monoaminergic hypothesis of major 
depression (MD) stipulates that a deficit in brain monoaminergic neurotransmission in 
various brain areas including the frontal cortex, hippocampus, amygdala or hypothalamus 
would account for some of signs and symptoms of the pathology (Katz et al., 2010a). For 
instance, abnormalities in the serotonin (5-HT) transmission are associated with impulsivity, 
aggressive, and anxious behaviors (Handley et al., 1995), whereas alteration in 
noradrenergic transmission, with motor activity, attention, and arousal (Morilak and Frazer, 
2004). The role of dopamine (DA) on the other hand, attracted less attention in the 
mechanisms of action underlying MD. However, the observations that reserpine, which 
depletes catecholamines, results in lowering mood (Schidkrautn 1965) or that an inhibition 
of tyrosine hydroxylase induces a worsening of depressive symptoms (Miller et al., 1996), 
strongly suggest that decreasing DA function may be of particular relevance. The fact that 
several symptoms observed in MD, including impaired motivation, concentration, and 
pleasure result from an attenuation of dopaminergic neurotransmission, strengthens the 
hypothesis that DA also regulates mood (Dunlop and Nemeroff, 2007).  
Most antidepressants approved, such as the selective serotonin reuptake inhibitors (SSRIs), 
the norepinephrine (NE) reuptake inhibitor (NRIs) or the dual serotonin/norepinephrine 
reuptake inhibitors (SNRIs), act by enhancing brain 5-HT and/or NE levels. Despite their 
therapeutic action, residual symptoms remain and may explain the fact that approximately 
50% of depressive individuals do not respond adequately to these agents (Berton and 
Nestler, 2006). The question can be asked as to whether these remaining symptoms are 
caused by the antidepressants or if they result from dysfunction in other neurotransmitters 
such as a blunted DA neurotransmission. In this context, a new generation of antidepressant 
drugs, the triple reuptake inhibitors (TRIs), has been developed with the hope to offer a 
clinically relevant advantage over single- or dual-acting agents (Guiard et al., 2009). Indeed, 
since TRIs simultaneously enhance extracellular levels of 5-HT, NE and DA 
neurotransmissions in various brain regions, this class of antidepressants could exert their 
therapeutic activity by treating more symptoms of MD and/or by attenuating some side 
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effects observed in response to traditional antidepressants. As an example, it is believed that 
the dopaminergic component of TRIs may prevent sexual dysfunctions induced by an 
increase in brain 5-HT.  
The present review describes the serotonergic, noradrenergic and dopaminergic pathways 
in the brain and the specific symptoms of depression under their control. Then it focuses on 
the preclinical in vitro and in vivo properties of TRIs. Indeed, the knowledge of their 
pharmacological properties may help better understand their mechanism of action and 
anticipate their putative efficacy over SSRIs, NRIs and SNRIs in humans. Finally, since over 
75% of depressed patients suffer from painful symptoms and that monoaminergic pathways 
control many of the psychological functions that are disturbed in depression and pain 
perception (Hache et al., 2011), this review addresses the possibility that TRIs may exert part 
of their antidepressant activity by preventing/reversing algesia in depressed patients.  
2. Monoaminergic pathways in the brain and their reciprocal interactions 
2.1 The serotonergic system 
Serotonin (5-HT) is present in most brain regions in the central nervous system. In the brain, 
serotonergic neurons originate within the brain stem. This system is comprised of a 
relatively small number of neurons that are clustered in nine phylogenetically conserved 
nuclei grouped into caudal (B1–B5) and rostral (B6–B9) nuclei including the dorsal and 
median raphe (DR and MR; respectively), with the former projecting to areas of the deep 
cerebellar nuclei, cortex, and spinal cord, whereas the latter extends an axonal network 
throughout the forebrain and cortices (Dahlström and Fuxe, 1964). Of particular relevance to 
mechanisms of MD are projections to structural correlates of emotionality including the 
amygdala, prefrontal and cingulated cortices, hypothalamus, and thalamus (Hornung 2003). 
Recently, 5-HT neurons have been classified based on genetic lineages. Specifically, 5-HT 
neuronal progenitors can be subdivided into subpopulations, which are discriminated by 
differing genetic transcription factors such as Pet-1 (Kiyasova et al., 2011; Hendricks, 2003). 
Indeed, this factor is required for the acquisition of serotonergic identity in a majority of 
neurons in the raphe nuclei including the dorsal and median raphe nuclei. However 
residual 5-HT neurons outline a unique subpopulation of raphe neurons with highly 
selective anatomical targets particularly the brain areas involved in stress responses with 
dense innervation to the basolateral amygdala, the paraventricular nucleus of the 
hypothalamus, and the intralaminar thalamic nuclei. It has thus been proposed the existence 
of Pet1-dependent and Pet1-resistant 5-HT neurons targeting different brain centers that 
might delineate the anatomical basis for a dual serotonergic control on stress responses 
(Kiyasova et al., 2011). 
2.2 The noradrenergic system 
The central noradrenergic neurotransmitter system originates from two distinct groups of 
cells in the brainstem (Dell’Osso et al., 2010). The main noradrenergic brain circuits are 
located in the locus coeruleus (corresponding to A4+A6 cell groups), which send 
noradrenergic projections throughout the neuroaxis innervating areas such as the frontal 
cortex, hippocampus and amygdala as well as the cerebellum (Dahlström and Fuxe, 1965). 
This ascending projection system is also referred to as the dorsal noradrenergic bundle. The 
locus coeruleus is basically involved in the responsiveness to external conditions and 
vigilance, providing pathways descending to the spinal cord and projecting throughout the 
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limbic system and diencephalon (Racagni and Brunello). Efferents from the lateral 
tegmentum (corresponding to A1, A2, A5 and A7 cell groups) have less extensive 
projections (Dahlström and Fuxe, 1965). They provide predominant innervation of the 
hypothalamus and also innervate areas of the septum and the extended amygdala nuclei 
including the bed nucleus of the stria terminalis (Moore and Card, 1984). Interestingly, 
noradrenergic and serotonergic systems overlap at several levels and are far away to be 
independent, both distributing to broad cortical areas (Brühl et al., 2010). Reciprocal 
projections between the major groups of 5-HT and NE cell bodies have been reported, 
creating ample opportunity for cross-modulation between these systems. For example, it is 
well established that NE stimulates the neuronal activity of 5-HT neurons in the DR 
(Mongeau et al., 1997). In a marked contrast, 5-HT projections from the DR nucleus to the 
locus coeruleus, impose a tonic inhibitory tone on the firing of NE neurons (Dremencov et 
al., 2009). 
2.3 The dopaminergic system 
Most DA-producing neurons in the brain are located in brainstem nuclei: the retro-rubro 
field (A8), the substantia nigra pars compacta (A9), and the ventral tegmental area (VTA) 
(A10) (Dunlop and Nemeroff, 2007). Projection pathways of the axons arising from these cell 
bodies follow specific pathways via the medial forebrain bundle to innervate specific cortical 
and subcortical structures, unlike the more diffuse innervation patterns of serotonergic and 
noradrenergic cells. The nigrostriatal pathway projects from the substantia nigra pars 
compacta to the dorsal striatum (caudate and putamen) and has a prominent role in the 
motor planning and execution of movement, although it clearly also plays an important role 
in non-motor functions, such as cognition (McClure et al., 2003). The mesocortical pathway 
arises from the VTA and projects to the frontal and temporal cortices, particularly the 
anterior cingulate, enthorinal, and prefrontal cortices. This pathway is believed to be 
important for concentration and executive functions such as working memory. The 
mesolimbic pathway also arises from the VTA but projects to the ventral striatum (including 
the nucleus accumbens), bed nucleus of the stria terminalis, hippocampus, amygdala, and 
septum. It is particularly important for motivation, the experience of pleasure and reward. 
The tuberoinfundibular pathway arises from the arcuate nucleus of the hypothalamus (A12) 
and projects to the median eminence of the hypothalamus, where DA released into the 
portal vessels acts to inhibit the secretion of prolactin from the anterior pituitary (Ben-
Jonathan and Hnasko, 2001). The incertohypothalamic pathway originates from cell bodies 
in the medial portion of the zona incerta (A13) and innervates amygdaloid and 
hypothalamic nuclei involved in sexual behavior. Unlike the other dopaminergic pathways, 
the "thalamic dopamine system" arises from multiple sites, including the periaqueductal 
gray matter and may contribute to the control of nociception (Hache et al., 2011). 
Importantly, serotonergic and noradrenergic neurons also display a high degree of 
anatomical and functional connectivity with the dopaminergic system. For instance, in 
addition to its tonic inhibition of NE transmission, 5-HT is believed to inhibit the firing of 
DA neurons in the VTA (Guiard et al., 2008a; 2008b). The influence of NE on DA neurons is 
more complex since both excitatory and inhibitory impacts have been reported (Guiard et 
al., 2008a; 2008b; Linner et al., 2001). On the other and, growing evidence suggest that DA 
may modulate the activity of 5-HT and NE neurons. It is suspected that DA directly 
increases the neuronal activity of 5-HT neurons in the DR (Haj-Dahmane, 2001; Martin-Ruiz 
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et al., 2001), thereby enhancing local 5-HT outflow (Ferre et al., 1994; Ferre and Artigas, 
1993; Martin-Ruiz et al., 2001). In contrast, multiple source of evidence demonstrates that 
DA inhibits the neuronal activity of NE neurons in the LC (Guiard et al., 2008a, 2008b; 
Deutch et al., 1986; Elam et al., 1986). 
3. Depression: monoaminergic symptoms and disturbances  
Based on the findings from studies of antidepressants, it may be possible to assign specific 
symptoms of depression to specific neurochemical mechanisms (Nutt, 2008a). Knowing 
which particular neurotransmitters are associated with particular symptoms of depression 
may help determine appropriate treatments that target specific mechanism that in turn 
target specific depression symptoms. 5-HT may be related to anxiety, compulsions and sleep 
disturbances; NE to alertness and energy as well as anxiety, attention, and interest in life; 
and DA to motivation, pleasure, and reward, as well as interest in life (Figure 1). Increasing 
any of these 3 neurotransmitters will elevate mood, but the other elements of depression 
may be particularly responsive to a certain neurotransmitter.  
 
 
Fig. 1. Monoamine regulation of mood behavior (Adapted from Nutt, 2008). 
3.1 Depressed mood and sadness 
Neuroimaging studies have associated depressed mood and sadness with abnormal 
neuronal activity in the medial prefrontal cortex (Drevets, 1999). This brain region receives 
innervation from serotonergic (midbrain raphe), noradrenergic (locus coeruleus) and 
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dopaminergic (ventral tegmental area) pathways. Low levels of these monoamines may 
decrease mood whereas antidepressants that enhance levels of monoamines have been 
shown to improve depressed mood and sadness (Morilak and Frazer, 2004). Other 
symptoms and/or comorbidities such as sleep or appetite disturbances as well as 
nociception may be affected in patients with MD and should draw attention of physicians 
when choosing antidepressants therapy. Clearly, an improved treatment of MD should start 
with a good diagnosis, based on the symptoms patients encounter as disturbances in 
different neurotransmitter systems. 
3.2 Diminished interest and pleasure 
Reduced dopaminergic activity has been linked to decreased motivation (Salamone et al., 
2003), anhedonia (loss of pleasure) and loss of interest (Willner, 1983), whereas increased 
dopaminergic transmission has been linked to positive affect (Depue and Collins, 1999). The 
mesocortical dopaminergic pathway, in particular the nucleus accumbens is a key regulator 
of pleasure. The prefrontal cortex is believed to be important in motivation (Drevets, 2001).  
A dysfunction of the mesocorticolimbic dopaminergic system innervating limbic structures 
including the nucleus accumbens, amygdala, ventral hippocampus and cortical areas may 
underlie the symptoms of loss of motivation, loss of interest and the inability to experience 
pleasure observed in MD. Antidepressants that enhance DA release including bupropion, 
may thus improve these symptoms (Dunlop and Nemeroff, 2007). 
3.3 Fatigue and loss of energy 
Brains areas controlling motor function such as the striatum innervated by DA and 5-HT 
neurons may be involved in physical fatigue, (Stahl et al., 2008). Mental fatigue and lack of 
mental energy may be related to other symptoms of depression, such as apathy (absence in 
feeling, emotion, interest) and lack of motivation. Cortical brain regions, especially the 
dorsolateral prefrontal cortex, are more likely to be involved in mental fatigue (MacHale et 
al., 2000). Consequently, antidepressants that increase DA and 5-HT, or both, may be 
preferable for patients with predominant symptoms of fatigue and loss of energy (Stahl et 
al., 2008). 
3.4 Anxiety 
The neuronal pathway of fears involved the amygdala, which receives NE and 5-HT 
innervation from the LC and DR, respectively. High levels of amygdala activation are 
associated with an increased prevalence of anxiety (Davidson et al., 2002) raising the 
possibility that antidepressants targeting both NE and 5-HT, may be more appropriate for 
treating depressed patients with comorbid anxiety disorders (Morilak and Frazer, 2004). 
3.5 Sleep disturbance 
There is a very strong association between sleep disturbance and major depression. 
Depressed patients usually complain of insomnia, notably of difficulties in falling asleep, 
frequent awakenings during the night, early waking up, and non-refreshing sleep (Benca 
et al., 1992). As well as distressing symptoms of sleep experienced by patients, changes in 
sleep architecture have been reported. Compared with normal controls, sleep continuity 
of depressed subjects is often impaired, with increased wakefulness (more frequent and 
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longer periods of wakefulness), and reduced sleep efficiency. Sleep onset latency is 
significantly increased and total sleep time reduced. Rapid eye movement (REM) latency 
is often shortened, and the duration of the first REM period is increased (Nutt et al., 
2008b). The role of 5-HT in the regulation of sleep is well documented and studies 
indicate that the neuronal activity of 5-HT and its release is maximal during wakefulness 
(W), reduced during slow wave sleep (SWS), and minimal during rapid eye movement 
(REM) sleep (Adrien, 2002).  Consequently, SSRIs, which increase 5-HT function increase 
REM latency, and reduce REM sleep (Wilson and Argyropoulos, 2005) may worsen sleep 
disturbance early in treatment (Hicks et al., 2002) and may leave residual sleep symptoms 
once mood is improved (Nelson et al., 2005). It is noteworthy that depressed patients may 
also display an excessive sleep and hypersomnia, particularly in atypical depression 
(Gold et al., 2002). This latter observation emphasizes the fact that a better diagnosis, 
based on the different subtypes of MD is a prerequisite to optimize and individualize 
antidepressant therapy. 
3.6 Appetite and eating disorders 
Eating disorders, the term now encompasses anorexia nervosa and bulimia nervosa 
(Jimerson et al., 1993), result from alteration, at least in part, in monoaminergic 
neurotransmission involved in the homeostatic control of appetite function. For example, 
positive correlations between mood disturbances and eating and weight concerns have 
been reported (Casper et al., 1998). Although, the background of eating disorders is 
complex, the involvement of impaired hypothalamic 5-HT function in these disorders is 
well documented (Wallin and Rissanen, 1994). In agreement with the observation that in 
this brain region, 5-HT contributes to post-ingestive satiety, several studies have shown 
that SSRIs, particularly fluoxetine, is effective in controlling bulimic episodes (Walsh, 
1994). This is also the case for other serotoninergic drugs, among them fenfluramine, 
which was used in the treatment of obesity (Guy-Grand, 1992). There is growing notion 
that mesolimbic dopaminergic neurotransmission also contributes to the effect of DA on 
feeding behavior (Volkow and Wise, 2005). Sibutramine, in addition to its effect on 5-HT, 
inhibits the reuptake of other monoamines and has been shown to enhance postprandial 
satiety, reduce total calorie intake and to diminish the decline in energy expenditure 
usually associated with a diet-induced negative energy balance (Hansen et al., 1999). 
Consequently, combined blockade of NE and 5-HT reuptake by SNRIs results in reduced 
food intake and body weight that neither monoamine reuptake inhibitor could achieve on 
its own. Interestingly, bupropion the dual NE releaser and DAT inhibitor (Dong and Blier, 
2001), cause weight loss by combined induction of hypophagia and thermogenesis (Billes 
and Cowley, 2007).  
Recently there has been interest in investigating the use of SSRIs in the treatment of patients 
with anorexia nervosa. Although fluoxetine has been associated with weight loss, it was 
proposed that this medication, because of a favorable side effect profile, could have 
advantages for treating depressive symptoms in patients with anorexia (Gwirtsman et al., 
1990).  
3.7 Nociception 
This is specifically illustrated in the fifth chapter of the present review. 
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4. Pharmacological properties of TRIs   
As described in the precedent chapter some comorbid symptoms of depression such as 
anhedonia, loss of motivation and concentration are directly connected to a deficit in central 
dopaminergic transmission. Consequently, triple reuptake inhibitors (TRIs) that 
simultaneously inhibit the reuptake of the three monoamines 5-HT, NE, DA (Chen & 
Skolnick, 2007) may provide greater symptomatic relief than SSRIs, NRIs or SNRIs. The 
interest of TRIs may also rely on the excitatory effect of DA upon the serotonergic system 
(Haj-Dahmane, 2001; Martin-Ruiz et al., 2001), thus suggesting that an increase in 
dopaminergic neurotransmission would facilitate that of 5-HT. In accordance with this 
hypothesis, it was shown that combination of SSRIs with bupropion lead to a synergy on 
monoamine transmission (Ghanbari et al. 2010; Prica et al. 2008; Li et al. 2002), as well as 
producing a robust antidepressant effect especially in treatment-resistant depressed patients 
 
 
Fig. 2. Monoaminergic antidepressants blocking the serotonin, norepinephrine and/or 
dopamine transporter. These agents are in various clinical* or preclinical** phases of 
development in MD or comorbidities. Selective serotonin reuptake inhibitor (SSRI), 
norepinephrine reuptake inhibitor (NRI), dopamine reuptake inhibitor (DRI), 
serotonin/norepinephrine reuptake inhibitor (SNRI), norepinephrine/dopamine reuptake 
inhibitor (NDRI), triple reuptake inhibitor (TRI). #This agent is a dopamine reuptake 
inhibitor and a norepinephrine releaser (Dong and Blier, 2001).  
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(Leuchter et al. 2008; Zisook et al. 2006). A number of compounds with the ability to bind and 
block all three monoamine transporters have been developed. DOV Pharmaceutical, Inc. is the 
first company having provided in vitro and in vivo preclinical data with their triple reuptake 
inhibitors DOV216303 and DOV21947. New molecules have followed such as NS2330 
(tesofensine, GlaxoSmith-Kline/NeuroSearch), SEP225289 (Sepracor Inc.), CNS-1 and CNS-2 
(Albany Molecular Research Institute Inc), PRC-025, PRC-050, PRC-200SS (Mayo Foundation), 
JNJ7925476 (Johnson & Johnson Pharmaceutical Research & Development), WF-23 (Eli Lilly) 
and JZAD-IV-22 (PsychoGenics). Lundbeck laboratories develop their own compounds such 
as LuAA24530 but with the difference that they also antagonize monoaminergic receptors. 
Others compounds will undoubtedly emerge in a near future. Indeed, it is interesting to note 
that in 2010-2011, the pharmacological profiles of nine new compounds, studying the structure 
activity relationship (SAR), have been reported (Shao et al., 2011a; 2001b; 2011c; Caldarone et 
al., 2010; Carter et al., 2010; Lee et al., 2010; Lucas et al., 2010; Micheli et al., 2010a, 2010b; 
Schoedel et al., 2010). Despite the emergence of these compounds, older molecules with the 
abilities to inhibit all three monoamines transporters were already available such as the 
tryciclic agent nefopam approved in Europe (Heel et al., 1980), bicifadine in phase III (Basile et 
al., 2007) or indatraline (Lengyel et al., 2008) (Figure 2). 
4.1 Preclinical in vitro properties 
4.1.1 Binding properties 
Many studies provide Kd values for their compounds, or Ki values, which are sometimes 
used interchangeably. These values for the SERT, NET and DAT are provided in Table 1. It 
can be noticed that some TRIs such as the PRC series preferentially bind to the SERT and 
NET while displaying a lower affinity for the DA transporter (DAT). This is, however, not 
the case for the other compounds which display a similar or higher affinity for the DAT than 
for the SERT or the NET. Interestingly, the affinity of most of these new compounds for 
monoamines transporters is lower than that of SSRIs and NRIs at binding SERT and NET, 
respectively (Hache et al., 2011). Therefore, the analysis of the binding properties and 
functional activity of the TRIs indicates that the novelty of these pharmacological agents lies 
in their relative balanced binding profile rather than in their potency at blocking 
monoamines transporters (Hache et al., 2011). 
 
TRIs 
In vitro binding 
(Ki or Kd in nM) References 
SERT NET DAT 
Bicifadinea 2400 5000 5200 Basile et al., 2007
Indatralinea 0.6 2 4 Lengyel et al., 2008
DOV216303a 190 380 190 Chen and Skolnick, 2007 
DOV21947a 110 260 210 Skolnick et al., 2003
JNJ7925476a 0.9 16 5 Aluisio et al., 2008
PRC025b 6 10 53 Shaw et al., 2007
PRC050b 12 1.2 43 Shaw et al., 2007
PRC200-SSb 2.1 1.5 61 Liang et al., 2008
Table 1. In vitro binding affinities of triple reuptake inhibitors (TRIs). aKi values are 
expressed in nM (Ki for inhibition of radioligand binding). bKd values are expressed in nM 
and represent the equilibrium dissociation constant. The smaller the Kd values, the higher 
affinity of a drug is for the corresponding monoaminergic transporter. 
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4.1.2 Functional activity: Synaptosomes 
Inhibition of [3H]-5-HT or [3H]-NE reuptake in synaptosomes, is one of the most widespread 
method to assess the in vitro potency of reuptake inhibitors (Sanchez and Hytell, 1999) and 
to predict indirectly, their selectivity on biogenic amines transporters. In addition, it is 
noteworthy that the binding properties of triple reuptake inhibitors do not necessarily 
correspond to their in vitro functional activity assessed from rat brain synaptosomes (Tables 
1 and 2). For example, although in vitro studies with PRC compounds (PRC025, PRC050 and 
PRC200SS: 1S,2S-isomer of racemic PRC050), revealed a perfect correlation between binding 
affinity and functional activity towards monaminergic transporters (i.e. the rank of potency 
is NET>SERT>DAT), DOV216303 which preferentially binds to SERT and DAT, mainly 
inhibits the uptake of [3H]5-HT and [3H]NE (Chen and Skolnick, 2007; Skolnick et al., 2003). 
Such a discrepancy could be explained by the fact that the uptake of [3H]NE from 
synaptosomal fractions involved the DAT. Indeed, unselective reuptake mechanisms have 
been previously reported with monoaminergic systems. In particular, it is well established 
that the clearance of DA from the extracellular space can occur through the NET in various 
brain regions including the hippocampus, the FC and the NAcc (Carboni et al., 2004; 
Bymaster et al., 2002; Moron et al., 2002). More recent evidence shows that DA may also be 
taken up by the SERT (Larsen et al., 2011). 
4.2 Preclinical in vivo properties 
In vivo strategies for characterizing the selectivity and potency of monoamines reuptake 
inhibitors examine the electrophysiological and neurochemical effects of these compounds, 
generally in rat or mouse brain. At presynaptic level, when the 5-HT or NE transporters are 
blocked on the serotonergic or noradrenergic cell bodies, respectively, there results an 
accumulation of 5-HT or NE in the vicinity of somatodendritic 5-HT1A or 2 autoreceptors 
in the dorsal raphe (DR) or locus coeruleus (LC). This lead to an attenuating firing of DR 5-
HT or LC NE neurons in a dose-dependent manner due to the activation of these neuronal 
elements exerting a negative feedback influence (Tremblay and Blier 2006). This parameter 
can be used to characterize the pharmacological profile of reuptake inhibitors. At nerve 
terminals, an accumulation of 5-HT or NE also occurs in response to the inactivation of the 
5-HT or the NE transporter by SSRIs or NRIs, and the enhancement of extracellular levels of 
monoamines can be probed by microdialysis in various brain regions (Guiard et al., 2009). 
This approach constitutes a second parameter to study the functional activity of reuptake 
inhibitors. Nevertheless, since microdialysis methodology may vary between laboratories, 
the electrophysiological approach seems to be more appropriate to establish relevant 
comparisons between compounds. 
4.2.1 Functional activity: Electrophysiology 
Electrophysiological recordings with TRIs (in comparison with single- or dual-acting agents) 
on monoamines neuronal activities have yet to be determined. Nevertheless, an initial study 
reported, that relative high intravenous doses of the TRIs SEP225289 and DOV216303 were 
required to inhibit the electrical activities of DR 5-HT, LC NE and VTA DA neurons. 
Although this may result from a lower affinity for the monoaminergic transporters than 
selective reupake inhibitors or from a poor brain penetration, 5 mg/kg; iv of DOV216303, 
produced an inhibition of 80% of LC NE neuronal activity but only of 30% and 40% of DR 5-
HT and VTA DA neurons; respectively (Guiard et al., 2011). The observation that both TRIs 
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exerted a predominant effect in the LC, while producing only a partial decrease in DR 5-HT 
firing activity was puzzling given the equal in vitro affinity and potency of the former drugs 
for all three transporters. The reciprocal interactions between monoaminergic neurons 
might have thus contributed to alter the functional in vivo activity of TRIs because the 
majority of SSRIs, NRIs and SNRIs produce a complete suppression of DR 5-HT neurons 
firing (Hache et al., 2011). The possibility has been raised that the lesser than expected effect 
of SEP225289 or DOV216303 on the firing activity of 5-HT neurons resulted, at least in part, 
from the accumulation of DA and NE in the DR, which are supposed, as abovementioned to 
be excitatory on the neuronal activity of 5-HT neurons (Katz et al., 2010b).  
4.2.2 Functional activity: Intracerebral microdialysis 
With respect to microdialysis data, as expected all TRIs increase extracellular monoamines 
levels with distinct intensities, depending on their pharmacological properties, on the brain 
regions studied and their relative equipment in monoamines transporters and, on the model 
used “naïve” vs depressed animal (Table 2). In a recent study performed in control rats, 
PRC200-SS was shown to increase the extracellular levels of the three monoamines in the 
medial prefrontal cortex cortex (mPFC) and the Nucleus accumbens (NAcc) (Liang et al., 
2008). In the mPFC, in agreement with its in vitro pharmacological profile, PRC200-SS (5 and 
10 mg/kg; ip) significantly increased extracellular levels of NE and 5-HT with a more 
pronounced effect for NE. Nevertheless, in this brain region PRC200-SS failed to modify the 
extracellular levels of DA. This result is somewhat surprising given the dense dopaminergic 
innervation and the high expression of DAT in the frontal cortex (Kuikka et al., 1995). The 
lack of increase in cortical DA extracellular levels may be explained by its heterologous 
reuptake from the NET (Moron et al., 2002; Giros et al., 1994). However the observations 
that catecholamine uptake blockers such as nomifensine, desipramine or GBR12909 increase 
DA levels (Devoto et al., 2004; Valentini et al., 2004; Gresh et al., 1995) could emphasize the 
importance of the reciprocal interactions between the DA and NE or 5-HT system at nerve 
terminal. Indeed if NE and/or 5-HT exert an inhibitory influence on cortical dopaminergic 
projections, as describe in the VTA (Guiard et al., 2008a), this might have produced counter-
productive effects. However, in the core of the NAcc, where the density of DAT is relatively 
high, PRC200-SS (10 mg/kg; ip) increased DA and, to a lower extent, 5-HT outflow without 
affecting NE, probably because of the absence of noradrenergic innervation in this brain 
area (Carboni et al., 2006). Using microdialysis in the cortex of freely moving rats, 
confirmation of the blocking activity of JNJ7925476 on the SERT, NET and DAT has also 
been provided. A robust and dose-dependent increase in all three monoamines, lasting for 
several hours, was detected with a maximal effect for DA compared to 5-HT and NE at the 
highest dose tested (10 mg/kg; sc) (Aluisio et al., 2008). These results strongly contrast with 
in vitro data showing that JNJ7925476 displayed a better in vitro binding affinity and 
blocking activity for SERT than for DAT (Aluisio et al., 2008). Differences in transporter 
occupancy cannot explain these findings since this parameter followed the same trend 
observed with cortical extracellular monoamines levels. It has therefore been proposed that 
the high cortical levels of DA might have resulted from the blockade of the NET by this 
drug, which displays a high affinity for the DAT (Moron et al., 2002; Giros et al., 1994). 
Another possibility would be that JNJ7925476 acted by stimulating the release of DA but this 
property has not been demonstrated yet. Indirect effects might have also involved 
functional interaction between monoaminergic neurons leading to high extracellular levels 
of cortical DA. Together, these findings illustrate the fact that the in vivo activity of TRIs does 
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not necessarily reflect their in vitro functional activity, probably due, at least in part, to 
functional interactions between monoaminergic neurons. Another interesting example of 
unexpected results comes from neurochemical studies with bicifadine. Indeed, microdialysis 
studies in normal waking rats indicated that bicifadine preferentially increase DA and 5-HT 
than NE extracellular levels in the nucleus accumbens at the highest dose tested (60 mg/kg; 
i.p.) despite the higher potency of this TRI at binding and inhibiting the SERT and NET 
(Nicholson et al., 2009; Basile et al., 2007). Although the selectivity of this compound at the 
dose tested can be questioned, it is possible that the combined elevation in 5-HT and DA 
produce robust inhibitory effect on the noradrenergic system.  
In olfactory bulbectomized rats, a model of depression (Song et al., 2005), it has been shown 
that the removal of olfactory bulbs results in a significant decreased in DA, but not 5-HT 
and NE, cortical extracellular levels when compared to sham operated. Interestingly, 
although after acute administration, DOV216303 increased DA, 5-HT and NE outflow in 
sham and bulbectomized rats, chronic administration resulted in a blunted rise in 
neurotransmitter (Prins et al., 2011; Prins et al., 2010). In the hippocampus, no changes in 
monoamines levels were observed in bulbectomized rats, DOV216303 increase DA, 5-HT 
and NE in both sham and bulbectomized rats either after acute or chronic treatment (Prins et 
al., 2011). This raises the possibility that monamines homeostasis in response to TRIs is 
regulated in a region-dependant manner. In the search for new drugs, adaptations in 
receptor and transporter density pre- and post-synaptically after chronic drug 
administration should be investigated as well. 
 
TRI 
In vitro uptake 
(Kd or IC50 in nM) 
In vivo uptake 
 References 
SERT NET DAT 5-HT NE DA 
Bicifadinea 117 55 910 +++ ++ +++ 
Nicholson et al., 
2009 ; Basile et al., 
2007 
DOV216303a 30 45 80 +++ ++ ++ 
Caldarone et al., 
2010 ; Prins et al., 
2010 
DOV21947a 12 23 96 ND ND ND 
Skolnick et al., 
2003 
JNJ7925476a 1 1 2.5 +++ +++ +++ Aluisio et al., 2008 
JZAD-IV-22a 15 84 120 ++ +++ +++ 
Caldarone  
et al., 2010 
PRC025b 6 19 100 ND ND ND Shaw et al., 2007 
PRC050b 6 0.4 120 ND ND ND Shaw et al., 2007 
PRC200-SSb 2 0.6 18 + +++ ++ Liang et al., 2008 
SEP225289a 14 4 2 ND ND ND Guiard et al., 2011 
Table 2. In vitro and in vivo functional activity of triple reuptake inhibitors (TRIs) from 
synaptosomes and intracerebral microdialysis; respectively. aValues are expressed in IC50. 
bValues are Kd expressed in nM and represent the equilibrium dissociation constant. The 
smaller the Kd values, the higher inhibitory effect of a drug is for the corresponding 
monoaminergic transporter. In microdialysis experiments, signs “+” reflects the relative 
increase in 5-HT, NE and DA obtained with the highest acute dose used. ND: not determined. 
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4.3 Antidepressant-like activity 
In humans, it is accepted that antidepressant and more particularly SSRIs, typically inhibit 
80% of the SERT binding sites at minimally effective doses (Blier, 2008). It is, however, not 
known how much inhibition or occupancy for each transporter is required for 
antidepressant action. Correlation between in vitro binding profile towards monoamines 
transporters and in vivo behavioral studies may help shed light on some important and often 
debated issues. 
4.3.1 In test predictive of antidepressant-like activity 
The most frequently paradigms used to screen the antidepressant-like activity of 
pharmacological agents are the forced swimming and the tail suspension tests (FST and TST, 
respectively). Interestingly in the FST a further distinction can be made in swimming and 
climbing behaviors. Swimming is a parameter that reflects the activation of the brain 
serotonergic system in rodents (Cryan and Lucki, 2000; Reneric and Lucki, 1998; Detke et al., 
1995). Such an association comes from the observation that pretreatment with the 
tryptophan hydroxylase inhibitor parachlorophenylalanine, prevents SSRIs-induced 
increase in swimming behavior (Page et al., 1999). On the other hand, climbing behavior has 
been shown to reflect the activation of noradrenergic system, particularly the subpopulation 
of neurons arising from the lateral tegmentum (Cryan et al., 2002). Surprisingly, none of the 
studies evaluating the antidepressant-like activity of TRIs has examined the climbing 
response, to compare for example, their in vivo potency at stimulating brain serotonergic 
and noradrenergic neurotransmissions. It is also important to mention that only one test in 
animals cannot cover all the complex depressive aspects. Ideally, novel compounds should 
be tested in several behavioral paradigms and animal models in order to address their 
putative antidepressant-like activity on a wide variety of symptoms of MD. In this prospect, 
Guilloux et al., (2011) have recently developed a score integrating measures from different 
tests to provide a robust characterization of the underlying "emotionality" of individual 
mouse, similarly as mood and related syndromes are defined in humans through various 
related symptoms over time.  
Behavioral data currently available, have clearly demonstrated the antidepressant-like effect 
of triple reuptake inhibitors that act by increasing the time of mobility and/or by reducing 
the time of immobility in the FST or the TST (Aluisio et al., 2008; Liang et al., 2008; Shaw et 
al., 2007; Skolnick et al., 2003) (Table 3). Among the TRIs tested, PRC200-SS and JNJ7925476 
produced the most robust antidepressant-like effects in these tests. For example, JNJ7925476 
(0.3 mg/kg; sc) or PRC200-SS (10mg/kg; ip) produced a greater increase in the time of 
mobility in the mouse TST than that observed with PRC025, PRC050 (Aluisio et al., 2008; 
Bannwart et al., 2008; Liang et al., 2008; Shaw et al., 2007; Skolnick et al., 2003). In the rat 
FST, PRC200-SS is also the compound exhibiting the best performance since at the dose of 10 
mg/kg; ip, it produced a more pronounced increase in the time of immobility than that 
observed with the corresponding doses of DOV21947, PRC025 and PRC050. Interestingly, 
both compounds (i.e. JNJ7925476 and PRC0200-SS) display a higher affinity for the SERT 
and the NET compared to the others compounds, suggesting that this double action is an 
important prerequisite to produce maximal effects. Since DA is known to enhance 
locomotor activity, the possibility cannot be excluded that triple reuptake inhibitors 
increased the time of immobility in these various studies, through a psychostimulant effect. 
In various studies, however, TRIs did not modify locomotor activity at doses that produce 
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antidepressant-like effects (Aluisio et al., 2008; Liang et al., 2008; Shaw et al., 2007; Skolnick 
et al., 2003), thus suggesting that the antidepressant-like activity of TRIs does not appear to 
be from “false-positive” results. 
4.3.2 In animal models of depression 
An important drawback in the development of antidepressants is the fact that the new 
compounds are tested after acute administration in “naïve” non-depressed animals. Their 
chronic use in animal models is likely more relevant and would provide more informative 
results to determine whether or not a new pharmacological agents worth being tested in 
clinical trials. A recent study in bulbectomized rats has provided some interesting results. In 
this model, a 14-day regimen of DOV216303 (20 mg/kg/day; po), normalized bulbectomy-
induced hyperactivity in the open field, similar to the effect of imipramine at the same dose 
(Breuer et al., 2008). Further studies in these animal models are required to precise the 
potential of TRIs and dissect their mechanism of action in pathological conditions. 
 
TRIs Doses, routes Tests 
Mobility 
(% of 
baseline 
increase) 
Immobility 
(% of baseline 
decrease) 
References 
DOV 216,303 
10 mg/kg; po
15 mg/kg; po
20 mg/kg; po
FST 
(mice) 
ND
ND 
ND 
-20%  (*)
-20%  (*) 
-40%  (*) 
Skolnick et al., 
2003 
DOV 21,947 
5 mg/kg; po
10 mg/kg; po
15 mg/kg; po
20 mg/kg; po
 
5 mg/kg; po
10 mg/kg; po
15 mg/kg; po
20 mg/kg; po
TST 
(mice) 
 
 
 
FST 
(rats) 
ND
ND 
ND 
ND 
 
ND 
ND 
ND 
ND 
-25%  (***)
-40%  (***) 
-40%  (***) 
-55%  (***) 
 
-20%  (*) 
-25%  (***) 
-30%  (***) 
-40%  (***) 
Skolnick et al., 
2003 
JNJ-7925476 0.3 mg/kg; po
TST
(mice) 
115% ND Aluisio et al., 2008 
PRC025 
5 mg/kg; ip 
10 mg/kg; ip
 
5 mg/kg; ip 
10 mg/kg; ip
 
TST 
(mice) 
 
FST 
(rats) 
+60%  (*) 
+60%  (*) 
 
+145%  (*) 
+100%  (*) 
-40%  (*) 
-40%  (*) 
 
-40%  (*) 
-30%  (*) 
Shaw et al., 2007 
PRC200-SS 
(active 
enantiomere of 
PRC050) 
 
5 mg/kg; ip 
10 mg/kg; ip
 
5 mg/kg; ip 
10 mg/kg; ip
 
TST 
(mice) 
 
FST 
(rats) 
+80%  (*) 
+70%  (*) 
 
+110%  (*) 
+165%  (*) 
 
-40%  (*) 
-80%  (*) 
 
 
-30%  (*) 
-55%  (*) 
Shaw et al., 2007 
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TRIs Doses, routes Tests 
Mobility 
(% of 
baseline 
increase) 
Immobility 
(% of baseline 
decrease) 
References 
PRC200-SS 
(active 
enantiomere of 
PRC050) 
 
0.5 mg/kg; ip
1 mg/kg; ip 
10 mg/kg; ip
 
1 mg/kg; ip 
5 mg/kg; ip 
10 mg/kg; ip
 
 
TST 
(mice) 
 
 
FST 
(rats) 
+40%   (*) 
+95% (**) 
+95% (**) 
 
+130%  (*) 
+246%  (*) 
+226%  (*) 
-40%    (*) 
-90%  (**) 
-90%  (**) 
 
-45%  (*) 
-85%  (*) 
-75%  (*) 
Liang et al., 2008 
JZAD-IV-22 
 
15 mg/kg; ip
30 mg/kg; ip
60 mg/kg; ip
 
15 mg/kg; ip
30 mg/kg; ip
60 mg/kg; ip
 
 
TST 
(mice) 
 
 
FST 
(mice) 
 
ND 
ND 
ND 
 
ND 
ND 
ND 
-15%  (ns) 
-30%  (*) 
-35%  (*) 
 
-20%  (ns) 
-40%  (*) 
-70%  (*) 
 
Caldarone et al., 
2010 
 
6-(3,4-
dichlorophenyl)-
1-[(methyloxy) 
methyl]-3-
azabicyclo[4.1.0]
heptane 
 
3 mg/kg; ip 
10 mg/kg; ip
30 mg/kg; ip
 
 
FST 
(mice) 
 
 
ND 
ND 
ND 
 
-30%  (**) 
-70%  (**) 
-90%  (**) 
Micheli et al., 
2010a 
1-(Aryl)-6-
[alkoxyalkyl]-3-
azabicyclo[3.1.0]
hexanes and  
6-(aryl)-6-
[alkoxyalkyl]-3-
azabicyclo[3.1.0]
hexanes 
1 mg/kg; ip 
3 mg/kg; ip 
10 mg/kg; ip
 
FST 
(mice) 
 
ND 
ND 
ND 
-20%  (ns) 
-40%  (*) 
-90%  (**) 
Micheli et al., 
2010b 
3-aryl-3-
azolylpropan-1-
amines 
 
3 mg/kg; po
 
 
 
10 mg/kg; po
 
 
TST 
(mice) 
 
 
FST 
(mice) 
 
ND 
 
 
 
ND 
-60%  (*) 
 
 
 
-15%  (*) 
 
 
Lee et al., 2010 
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TRIs Doses, routes Tests 
Mobility 
(% of 
baseline 
increase) 
Immobility 
(% of baseline 
decrease) 
References 
4-(3,4-
dichlorophenyl)-
N-methyl-
1,2,3,4-
tetrahydronapht
halenyl amines 
(compound#10) 
3 mg/kg; ip 
10 mg/kg; ip
30 mg/kg; ip
 
TST 
(mice) 
 
ND 
-15% 
-20%  (*) 
-50%  (*) 
Shao et al., 2011a 
 
N-methyl-1-(1-
phenylcyclohexyl)
methanamine 
(compound #1) 
3 mg/kg; ip 
10 mg/kg; ip
30 mg/kg; ip
 
TST 
(mice) 
ND 
-5% 
-10% 
-25%  (*) 
 
Shao et al., 2011b 
 
N-methyl-1-(1-
phenylcyclohexyl)
methanamine 
(compound #31)
 
3 mg/kg; ip 
10 mg/kg; ip
30 mg/kg; ip
TST 
(mice) 
ND 
-10% 
-14% (*) 
-30%  (*) 
Shao et al., 2011c 
Table 3. Antidepressant-like activity of triple reuptake inhibitors (TRIs) in rodents assessed 
in the forced swimming test (FST) or the tail suspension test (TST). Po: per os; ip: 
intraperitoneal; ND: not determined. *p<0.05, **p<0.01 and p<0.001: significantly different 
from vehicle-treated group. 
4.4 Clinical properties of TRIs 
On the basis of preclinical data, TRIs are in process of development (Millan, 2009) and most 
are now in Phase II clinical trials (Table 4). A small citalopram-controlled trial of DOV216303 
in severely depressed patients yielded significant improvements in Hamilton Depression 
Rating Scale (HAM-D) scores in both groups at both one-week and two week time points 
(Skolnick et al., 2006). Since the optimal selectivity of TRIs at the three transporter sites 
remains undetermined, it is plausible that different potency ratios may result in different 
clinical effects. It can be envisaged to adapt the treatment to the nature of depressive 
symptoms. Drugs with high affinities for the 5-HT and NE transporters could be prescribed 
to patients displaying anxious symptoms, whereas compounds with a high affinity for the 
DAT could be more beneficial to patients having a loss of motivation and/or anhedonia. 
Despite these encouraging data, further investigations failed to demonstrate the beneficial 
therapeutic effect of NS2359 resulting in discontinued development. Of particular 
importance, a concern with drugs that block DA transporters is their potential reinforcing 
property and abuse liability. This comes from the fact that drugs that block DAT do not 
necessarily lead to dependence. Indeed, Volkow and collaborators showed that DA-
transporter-blocking drugs must induce more than 50% DAT blockade to produce 
reinforcing effects (Volkow et al., 2005). Hence, DA reuptake inhibitors have been classified 
into two groups: type 1 blockers, which produce addiction and euphoria, and type 2 
blockers, which do not (Rothman, 1990). It is thus possible that the capacity of DA reuptake 
blockers to produce dependence may involve other mechanisms that should carefully be 
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considered with multi-targets agents such as TRIs. Nevertheless, although rigorous clinical 
feedback is yet to come, it can be hoped that TRIs will prove to have acceptable abuse and 
dependence potential and will offer improved efficacy in the management of depression. 
Accordingly a recent study involving comparing tesofensine vs. placebo, D-amphetamine 
and bupropion, in recreational stimulant users shows that although the effects of D-
amphetamine were significantly greater than those of placebo on all primary and secondary 
subjective measures, tesofensine were not significantly different from those of placebo and 
lower than those of D-amphetamine and bupropion suggesting that the abuse potential for 
tesofensine is no greater than that of bupropion (Schoedel et al., 2010). Similar conclusions 
were reported with bicifadine, which display a low abuse potential (Nicholson et al., 2009). 
With respect to MD and eating disorders, weight loss has also been observed as an adverse 
event in studies with tesofensine (Hauser et al., 2007; Hansen et al., 2010), prompting further 
research for the indication of obesity. This effect is believed to result from appetite 
suppression (Axel et al., 2010; Sjodin et al., 2010). Recently published data from the first 
randomized, double-blind, Pl-controlled phase-II trial in primarily healthy, obese subjects 
showed that tesofensine was able to produce a greater weight loss after 24 weeks about 
twice that of currently approved drugs (Astrup et al., 2008a, 2008b). Appetite was 
significantly suppressed after an overnight fast after treatment with tesofensine in this study 
(Astrup et al., 2008a, 2008b). 
5. Pain relief by TRIs, an example of symptom of depression   
Acute and chronic pains may result from reduced levels of endogenous 5-HT, NE and DA 
activities, at both the spinal and supraspinal levels (Ren and Dubner, 2002). Indeed, pain is a 
bi-directional process of ascending and descending neuronal pathways involving 
monoaminergic systems whose activation may have an inhibitory influence on nociception. 
Despite the complexity of pharmacological interactions between monoaminergic neurons, 
that sometimes may attenuate monoaminergic neurotransmission, one would expect a better 
efficacy of dual-or triple-acting agents over selective 5-HT or NE reuptake inhibitors in 
analgesia (Hache et al., 2011). Indeed, since all three monoamines are involved in 
antinociception, the recruitment of more than one system may produce additional effects. 
Selected antidepressants suppress pain by diverse mechanisms and are now considered as 
an essential component of the therapeutic strategy for treatment of many types of persistent 
pain (Sawnyok et al., 2001). Their main mechanism of action involves reinforcement of the 
descending inhibitory pathways by increasing the amount of 5-HT and NE, but also DA in 
the synaptic cleft at both supraspinal and spinal levels (Hache et al., 2011). Several open-
label randomized controlled clinical trials, meta-analyses, and systematic reviews have 
confirmed the clinical efficacy of selected antidepressants in persistent pain conditions 
(Dharmshaktu et al., 2011). Precedent for the use of TRIs in the treatment of clinical pain 
exists with nefopam, a tricyclic agent with non-narcotic analgesic (Heel et al., 1980). It was 
reported that DA played a critical role in nefopam analgesia as indicated by the observation 
that rats with selective loss of DA neurons, have a marked reduction in nefopam-induced 
analgesia. In a marked contrast, the lesion of the serotonergic or noradrenergic systems 
induced by 5,7-duhydroxytryptamine (5,7-DHT) or DSP4, respectively, failed to affect 
nefopam-induced analgesia in rats (Esposito et al., 1986; Girard et al., 2006; Girard et al., 
2011). The potential interest of TRIs in the relief of pain has been corroborated by a recent 
publication characterizing the antinociceptive effects of the TRI bicifadine in acute, 
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persistent and chronic models of pain (Basile et al., 2007). In this study, bicifadine potently 
suppressed pain responses in two models of acute inflammatory pain in both rats and mice. 
It also normalized the nociceptive threshold in the complete Freund's adjuvant model of 
persistent inflammatory pain and suppressed mechanical and thermal hyperalgesia and 
mechanical allodynia in the spinal nerve ligation model of chronic neuropathic pain. 
Mechanical hyperalgesia was also reduced by bicifadine in the STZ model of neuropathic 
pain (Basile et al., 2007). Clinical (phase II/III) studies have demonstrated that bicifadine is 
an effective analgesic in the treatment of postoperative pain (Krieter et al., 2008). The impact 
of bicifadine on 5-HT, NE and DA neurotransmissions was confirmed by in vitro binding 
assays and intracerebral in vivo microdialysis study in freely moving rats. In a second study, 
another TRI, NS7051, has shown comparable antinociceptive properties to tramadol 
confirming the interest of these antidepressants in the relief of pain (Munro et al., 2008). The 
molecule has undergone several Phase II and III trials for the treatment of pain, including 
acute postsurgical pain and chronic low back pain, and is being evaluated for painful 
diabetic neuropathy (clinical trial.gov). However, bicifadine has failed to meet endpoints in 
a number of trials such as diabetic neuropathy (clinical trial.gov) suggesting that TRIs may 
be used in specific pain. Other TRIs currently under development for depression should 
draw attention for future investigations in the field of pain and confirm whether or not they 
display any activity in diabetic neuropathy. 
6. Conclusion 
Numerous arguments support the contention that multi-target mechanisms may be more 
effective and better tolerated than their highly selective counterparts in the management of 
MD (Millan, 2009).  Hence, drugs in preclinical and clinical studies (Table 4) include, but are 
not limited to TRIs, which simultaneously increase brain 5-HT, NE and DA 
neurotransmissions. Several lines of evidence specifically substantiate interest in dual-and 
triple-acting antidepressants. First there is no single cause of major depression. A vast array 
 
 
TRIs 
 
 
Comparator(s) 
 
 
Phases 
 
 
Conditions 
 
Tesofensine placebo I Obesity 
Tesofensine placebo II Obesity 
DOV21947 placebo II 
Major Depressive 
Disorder 
SEP225289 
placebo 
venlafaxine 
II 
Major Depressive 
Disorder 
Bicifadine 
placebo 
standard analgesic treatment
III Chronic low back pain 
Nefopam 
dexmedetomidine 
fentanyl 
IV Post operative analgesia 
Table 4. Clinical studies with triple reuptake inhibitors (TRIs) in major depressive disorder 
or related morbidities. Details of these studies can be found on 
http://www.clinicaltrials.gov using the Boolean research for the following keywords: 
“Triple reuptake inhibitors”. 
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of interacting genes, epigenetic influences, developmental events, and environmental factors 
collectively compromise mood.  Second, agents that have complementary components of 
action may have a greater chance of controlling both the mood deficits of depression and 
other residual symptoms such as sleep disturbances, eating, sexual disorders or pain. This 
review particularly focuses on nocicpetion since over 75% of depressed patients suffer from 
painful symptoms (Hache et al., 2011), predicting a greater severity and a less favorable 
outcome of depression. In addition, imaging, anatomical and functional studies have 
demonstrated the existence of common brain structures, neuronal pathways and 
neurotransmitters in depression and pain raising the possibility that managing pain in 
depressed patients may help them recover more rapidly and efficiently. This is an example 
illustrating the fact that MD does not rely on only one impaired system and that an 
improved antidepressant therapy requires a diagnosis taking into considerations symptom 
profiles. 
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